Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics

Human Psychopharmacology

Volumn 23, Issue 5, 2008, Pages 417-424

  Martinotti, Giovanni ^a,b,e   Andreoli, S ^a,b   di Nicola, M ^a,b   di Giannantonio, M ^c   Sarchiapone, M ^d   Janiri, L ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Casa di Cura Neuropsichiatrica Villa Maria Pia   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF MOLISE   (Italy)

^e Clinica Villa Maria Pia   (Italy)

Author keywords

Alcohol; Dual diagnosis; Quetiapine; Relapse prevention

Indexed keywords

ALCOHOL; QUETIAPINE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHAVIOR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; DETOXIFICATION; DIZZINESS; DRINKING BEHAVIOR; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HAMILTON SCALE; HUMAN; INSOMNIA; MALE; MEAN CORPUSCULAR VOLUME; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; PRIORITY JOURNAL; RECURRENCE RISK; SEDATION; SIDE EFFECT; SYMPTOM; VISUAL ANALOG SCALE; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA; CLINICAL TRIAL; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DUAL (PSYCHIATRY); DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE;

EID: 48249140622     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.944     Document Type: Article

References (44)

1. Bailey LG, Maxwell S, Brandabur MM. 1997. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Psychopharmacol Bull 33(1): 177-181.
2. Bellino S, Paradiso E, Bogetto F. 2006. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry 67(7): 1042-1046.
3. Benazzi F. 2006. Borderline personality-bipolar spectrum relationship. Prog Neuropsychopharmacol Biol Psychiatry 30(1): 68-74.
4. Bowers MB Jr, Mazure CM, Nelson JC, Jatlow PI. 1990. Psychotogenic drug use and neuroleptic response. Schizophr Bull 16(1): 81-85.
5. Brow ES. 2005. Bipolar disorder, substance abuse (Review). Psychiatr Clin North Am 28(2): 415-425.
6. Calabrese JR, Keck PE Jr, Macfadden W, et al. 2005. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162(7): 1351-1360.
7. Carlsson C, Gullberg B. 1978. A double blind study with melperone and placebo in the treatment of chronic alcoholics. Int J Clin Pharmacol Biopharm 16(7): 331-332.
8. Cassidy F, Ahearn EP, Carroll BJ. 2001. Substance abuse in bipolar disorder. Bipolar Disord 3(4): 81-188.
9. Chengappa KN, Levine J, Gershon S, Kupfer DJ. 2000. Lifetime prevalence of substance or alcohol abuse and dependence among subjects with bipolar I and II disorders in a voluntary registry. Bipolar Disord 2(3 Pt 1): 191-195.
10. Croissant B, Klein O, Gehrlein L, et al. 2006. Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series. Eur Psychiatry 21(8): 570-573.
11. Drake RE, Xie H, McHugo GJ, Green AL. 2000. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26(2): 441-419.
12. Foster JH, Peters TJ. 1999. Impaired sleep in alcohol misusers and dependent alcoholics and the impact upon outcome. Alcohol Clin Exp Res 23(6): 1044-1451.
13. Green AI, Zimmet SV, Strous RD, Schildkraut JJ. 1999. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry 6(6): 287-296.
14. Hochenegg L. 1981. Clopentixol decanoate in the treatment of chronic alcoholism. Acta Psychiatr Belg 81(2): 121-127.
15. Istituto Nazionale di Statistics (ISTAT). 2006. L'uso e l'abuso di alcol in Italia. April, available at: www.istat.it/salastampa/comunicati
16. Kampman KM, Pettinati HM, Lynch KJ, et al. 2007. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of type A and type B alcoholism. J Clin Psychopharmacol 27: 344-351.
17. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. 2000. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arc Gen Psychiatry 57(6): 553-559.
18. Khantzian EJ. 1985. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 142(11): 1259-1264.
19. Landheim AS, Bakken K, Vaglum P. 2006. Impact of comorbid psychiatric disorders on the outcome of substance abusers: a six year prospective follow-up in two Norwegian counties. BMC Psychiatry 20(6): 44.
20. Landolt HP, Gillin JC. 2001. Sleep abnormalities during abstinence in alcohol-dependent patients. Aetiology and management. CNS Drugs 15(5): 413-425.
21. Lejoyeux M, Solomon J, Ades J. 1998. Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol Nov-Dec 33(6): 563-575.
22. Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG. 2001. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 21(4): 217-221.
23. Longoria J, Brown ES, Perantie DC, Bobadilla L, Nejtek VA. 2004. Quetiapine for alcohol use and craving in bipolar disorder. J Clin Psychopharmacol 24(1): 101-102.
24. Mackinnon DF, Pies R. 2006. Affective instability as rapid cycling: theoretical and clinical implications for borderline personality and bipolar spectrum disorders. Bipolar Disord 8(1): 1-14.
25. McKowen JW, Frye MA, Altshuler LL, Gitlin MJ. 2005. Patterns of alcohol consumption in bipolar patients comorbid for alcohol abuse or dependence. Bipolar Disord 7(4): 377-381.
26. McLellan TA, Kushner H, Metzger D, et al. 1992. The 5th edition of the Addiction Severity Index. J Subst Abuse Treat 9(3): 199-213.
27. Monnelly EP, Ciraulo DA, Knapp C, et al. 2004. Quetiapine for the treatment of alcohol dependence. J Clin Psychopharmacol 24: 532-535.
28. Nace EP, Saxon JJ Jr, Shore N. 1986. Borderline personality disorder and alcoholism treatment: a one-year follow-up study. J Stud Alcohol 47(3): 196-200.
29. Nasrallah HA, Tandon R. 2002. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry 63 (Suppl. 13): 12-20.
30. Nemeroff CB, Kinkead B, Goldstein J. 2002. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63(Suppl 13): 5-11. Review.
31. Overall JE. 1973. Drug treatment of anxiety and depression in detoxified alcoholic patients. Arch Gen Psychiatry 29(2): 218-225.
32. Perrella C, Carrus D, Costa E, Schifano F. 2007. Quetiapine for the treatment of borderline personality disorder, an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 31(1): 158-163.
33. Sattar SP, Bhatia SC, Petty F. 2004. Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci 29(6): 452-457.
34. Siris SG. 1990. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 16(1): 111-122.
35. Sobell LC, Sobell MB. 1981. Effects of three interview factors on the validity of alcohol abusers' self-reports. Am J Drug Alcohol Abuse 8(2): 225-237.
36. Swendsen JD, Merikangas KR, Canino GJ, Kessler RC, Rubio-Stipec M, Angst J. 1998. The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities. Compr Psychiatry 39(4): 176-184.
37. Tarazi FI, Zhang K, Baldessarini RJ. 2002. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 161(3): 263-270.
38. Tsuang JW, Eckman TE, Shaner A, Marder SR. 1999. Clozapine for substance-abusing schizophrenic patients. Am J Psychiatry 156(7): 1119-1120.
39. Tupala E, Tiihonen J. 2004. Dopamine and alcoholism: neurobiological basis of ethanol abuse. Prog Neuropsychopharmacol Biol Psychiatry 28(8): 1221-1247.
40. Vaglum P. 2005. Personality disorders and the course and outcome of substance abuse: a selective review of the 1984 to 2004 literature. In Personality Disorders: Current Research and Treatments, Reich J (ed.). Routledge: New York; 105-124.
41. Vieta E, Parramon G, Padrell E, et al. 2002. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 4(5): 335-340.
42. Walter H, Ramskogler K, Semler B, Lesch OM, Platz W. 2001. Dopamine and alcohol relapse: D1 and D2 antagonists increase relapse rates in animal studies and in clinical trials. J Biomed Sci 8(1): 83-88.
43. Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR. 2004. Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. Am J Psychiatry 161(11): 2108-2114.
44. Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. 2000. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 20(1): 94-98.